حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
تاريخ الأرباح CPRX
تحليلات الأرباح CPRX
Max Ratio
–نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–Catalyst Pharmaceuticals Inc
CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Analytics
سعر الهدف في وول ستريت
34.29 USDنسبة السعر إلى الأرباح
13.39العائد الربحي
–المالية CPRX
نتائج | 2019 | ديناميات |